Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

Cell loss in the brain relates to variations in individual symptoms in Huntington’s disease

, 26 August 2020/in E-News /by 3wmedia

Scientists have wrestled to understand why Huntington’s disease, which is caused by a single gene mutation, can produce such variable symptoms. An authoritative review by a group of leading experts summarises the progress relating cell loss in the striatum and cerebral cortex to symptom profile in Huntington’s disease, suggesting a possible direction for developing targeted therapies
Huntington’s disease (HD) is an inherited progressive neurological disorder for which there is presently no cure. It is caused by a dominant mutation in the HD gene leading to expression of mutant huntingtin (HTT) protein. Expression of mutant HTT causes subtle changes in cellular functions, which ultimately results in jerking, uncontrollable movements, progressive psychiatric difficulties, and loss of mental abilities.
Although it is caused by a single gene, there are major variations in the symptoms of HD. The pattern of symptoms shown by each individual during the course of the disease can differ considerably and present as varying degrees of movement disturbances, cognitive decline, and mood and behavioural changes. Disease duration is typically between ten and twenty years.
Recent investigations have focused on what the presence of the defective gene does to various structures in the brain and understanding the relationship between changes in the brain and the variability in symptom profiles in Huntington’s disease.
Analyses of post-mortem human HD tissue suggest that the variation in clinical symptoms in HD is strongly associated with the variable pattern of neurodegeneration in two major regions of the brain, the striatum and the cerebral cortex. The neurodegeneration of the striatum generally follows an ordered and topographical distribution, but comparison of post-mortem human HD tissue and in vivo neuro-imaging techniques reveal that the disease produces a striking bilateral atrophy of the striatum, which in these recent studies has been found to be highly variable.
‘What is especially interesting is that recent findings suggest that the pattern of striatal cell death shows regional differences between cases in the functionally and neurochemically distinct striosomal and matrix compartments of the striatum which correspond with symptom variation,’ says author Richard L.M. Faull, MB, ChB, PhD, DSc, Director of the Centre for Brain Research, University of Auckland, New Zealand.
‘Our own recent detailed quantitative study using stereological cell counting in the post-mortem human HD cortex has complemented and expanded the neuroimaging studies by providing a cortical cellular basis of symptom heterogeneity in HD,’ continues Dr Faull. ‘In particular, HD cases which were dominated by motor dysfunction showed a major total cell loss (28% loss) in the primary motor cortex but no cell loss in the limbic cingulate cortex, whereas cases where mood symptoms predominated showed a total of 54% neuronal loss in the limbic cingulate cortex but no cell loss in the motor cortex. This suggests that the variable neuronal loss and alterations in the circuitry of the primary motor cortex and anterior cingulate cortex associated with the variable compartmental pattern of cell degeneration in the striatum contribute to the differential impairments of motor and mood functions in HD.’
The authors note that there are still questions to be answered in the field of HD pathology, such as, how and when pathological neuronal loss occurs; whether the progressive loss of neurons in the striatum is the primary process or is consequential to cortical cell dysfunction; and how these changes relate to symptom profiles.
‘What is clear however is that the diverse symptoms of HD patients appear to relate to the heterogeneity of cell loss in both the striatum and cerebral cortex,’ the authors conclude. ‘While there is currently no cure, this contemporary evidence suggests that possible genetic therapies aimed at HD gene silencing should be directed towards intervention at both the cerebral cortex and the striatum in the human brain. This poses challenging problems requiring the application of gene silencing therapies to quite widespread regions of the forebrain which may be assisted via CSF delivery systems using gene suppression agents that cross the CSF/brain barrier.’ EurekAlert

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:19Cell loss in the brain relates to variations in individual symptoms in Huntington’s disease

Sperm length variation is not a good sign

, 26 August 2020/in E-News /by 3wmedia

Perhaps variety is the very spice of life, but as a matter of producing human life, it could be the bane of existence. That’s the indication of a new study that found men with wider variation in sperm length, particularly in the flagellum, had lower concentrations of sperm that could swim well. Those with more consistently made sperm seemed to have more capable ones.
‘Our study reveals that men who produce higher concentrations of competent swimming sperm also demonstrate less variation in the size and shape of those sperm,’ said Jim Mossman, a postdoctoral scholar at Brown University and lead author of the paper. ‘It suggests that in some cases, testes are working more optimally to produce high numbers of consistently manufactured sperm, and vice versa.’
At the University of Sheffield, where Mossman did his doctoral studies, he and his co-authors measured the heads, midpieces, and flagella of 30 sperm per man, from 103 men randomly selected from a pool of about 500 who were recruited for a larger fertility study. They also measured other characteristics of each man’s semen, such as sperm concentration and motility, that the World Health Organisation recognises as important markers of fertility.
‘The WHO suggests that measurements should be made on multiple components of sperm, but generally it’s only the sperm head that is considered,’ Mossman said. ‘No one’s ever looked at this before across sperm components. What we show is that measurements on other sperm parts, such as the flagellum that propels the sperm, can provide additional information about the quality and consistency of sperm manufacture.’
The result of the novel analysis yielded two overall findings. One was that men who had higher mean flagellum length, total sperm length, and flagellum-to-head length ratios had higher concentrations of motile sperm. But perhaps the more interesting finding was that the greater the inconsistency of length in the sperm a man manufactures, particularly with regard to the flagellum, the lower his concentration of sperm that could swim well.
‘The finding could give clinicians new insight into the diagnosis and treatment of male fertility problems, which accounts for up to 50 percent of the cases where couples struggle to conceive,’ Mossman said. The research suggests that at least in some men, measurable inconsistency in sperm length may be a sign of trouble with his process of making sperm, a process known as spermatogenesis. That trouble, akin to a manufacturing line with poor quality control, could result in a lower concentration of good swimmers. Brown University

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:26Sperm length variation is not a good sign

Early menopause associated with increased risk of heart disease, stroke

, 26 August 2020/in E-News /by 3wmedia

Women who go into early menopause are twice as likely to suffer from coronary heart disease and stroke, new Johns Hopkins-led research suggests. The association holds true in patients from a variety of different ethnic backgrounds, the study found, and is independent of traditional cardiovascular disease risk factors, the scientists say.
‘If physicians know a patient has entered menopause before her 46th birthday, they can be extra vigilant in making recommendations and providing treatments to help prevent heart attacks and stroke,’ says Dhananjay Vaidya, Ph.D., an assistant professor in the Division of General Internal Medicine at the Johns Hopkins University School of Medicine, and leader of the study.
‘Our results suggest it is also important to avoid early menopause if at all possible.’
For example, he says, research has shown that smokers reach menopause, on average, two years earlier than non-smokers do, so quitting smoking may delay it.
Notably, the researchers said, their findings about the negative impact of early menopause were similar whether the women reached it naturally or surgically, via removal of reproductive organs, he says, though more research is needed. Often, Vaidya says, women who undergo hysterectomies have their ovaries removed, which precipitates rapid menopause. ‘Perhaps ovary removal can be avoided in more instances,’ he says, which might protect patients from heart disease and stroke by delaying the onset of menopause.
Cardiovascular disease is the number one killer of women in the United States, according to the Centers for Disease Control and Prevention.
Previous studies, Vaidya says, have shown a link between early menopause and heart disease and stroke among white women, but similar associations had not been demonstrated in more diverse populations. Hispanic and African-American women, he says, tend, on average, to go through menopause somewhat earlier than women of European descent.
Vaidya and his colleagues examined data from 2,509 women involved in the Multi-Ethnic Study of Atherosclerosis, a longitudinal, ethnically diverse cohort study of men and women aged 45 to 84 years, all enrolled between 2000 and 2002 and followed until 2008. Of the women, 28 percent reported early menopause, or menopause that occurs before the age of 46. Vaidya emphasizes that although the risk of heart attack and stroke was doubled in these groups, the actual number of cardiac and stroke events recorded among study participants was small. Only 50 women in the study suffered heart events, while 37 had strokes.
Menopause is a process during which a woman’s reproductive and hormonal cycles slow, her periods (menstruation) eventually stop, ovaries stop releasing eggs for fertilization and produce less estrogen and progesterone, and the possibility of pregnancy ends. A natural event that takes place in most women between the ages of 45 and 55, menopausal onsets and rates are influenced by a combination of factors including heredity, smoking, diet and exercise.
Vaidya says some women are treated with hormone replacement therapy (HRT) to control menopause symptoms such as profuse sweating and hot flashes, but its widespread long-term use has been limited after large clinical trials showed that it increased the risk of heart attacks in some women. In Vaidya’s study, no role was detected for HRT in potentially modifying the impact of early menopause.
‘Cardiovascular disease processes and risks start very early in life, even though the heart attacks and strokes happen later in life,’ he says. ‘Unfortunately, young women are often not targeted for prevention, because cardiovascular disease is thought to be only attacking women in old age. What our study reaffirms is that managing risk factors when women are young will likely prevent or postpone heart attacks and strokes when they age.’ Johns Hopkins

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:34Early menopause associated with increased risk of heart disease, stroke

The current state of lung cancer treatment

, 26 August 2020/in E-News /by 3wmedia

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.
‘We’re in a new paradigm in which we realize this top cause of cancer deaths is actually a number of related diseases, each potentially with its own cause and cure,’ Bunn says.
The review describes the shift from blanketing lung cancer with radiation and chemotherapy, to targeting the specific genetic mutations that cause lung cancer’s many varieties. The first of these oncogenic lung cancer mutations to be exploited by a drug was the epidermal growth factor receptor (EGFR), described in 2004 and targeted by the drugs erlotinib and gefitinib. Then in 2007 the oncogenic ALK/EML4 fusion protein was described, and is now targeted by the drug crizotinib, which earned FDA approval in 2011. Drugs in the development pipeline target a handful of additional lung-cancer-causing mutations including KRAS, HER2/neu, BRAF, NRAF, and ROS.
‘Pathologists used to define lung cancer as one of four types, based on its appearance,’ Bunn says, ‘but it’s much more heterogenous than that. Some of these driver mutations may only be present in 1 or 2 percent of the lung cancer population, and mutations in combination may make for hundreds of species of the disease, each with its own response characteristics to targeted drugs and drug combinations.’
‘Whole exome sequencing shows there are about 300 mutations in the average lung cancer,’ Bunn says. ‘You may have an EGFR mutation driving the cancer, but then the other 299 mutations may help define who will do well on an EGFR inhibitor.’
Bunn points out that in the lung cancer varieties whose driver oncogenes can be matched with targeted therapy, we tend to see 70-80 percent patient response as opposed to 20-30 percent response to traditional chemotherapies, and with much reduced side effects.
But with this great promise of picking off cancer varieties one-by-one according to their oncogenes comes the challenge of testing drugs that are effective in perhaps only one of every 100 lung cancer patients. The challenge is twofold: enrolling enough patients on a clinical trial to make the results meaningful, and securing funding for a trial in which the drug will only be marketable to a small slice of the lung cancer population.
‘How do you get drug approvals for what we’d normally call orphan diseases?’ Bunn asks.
Then, Bunn points to the major challenge of staying ahead of lung cancer as it mutates in response to these targeted first-line drugs. ‘Targeted therapies don’t cure patients yet,’ Bunn says. Instead, lung cancer eventually mutates around the drug’s effectiveness. ‘And so we have to discover the most rational combinations and see if these combinations allow complete response,’ Bunn says.
In addition to therapies targeting oncogenes, Bunn describes completely new approaches to treating the disease, including Phase III clinical trials of lung cancer vaccines that aid the body’s immune response against the cancer, and the search for ways to promote the function of tumour-suppressor genes that are commonly turned off in cancers.
What is clear is that after many years of chemotherapy and radiation, we’re in the midst of an explosion in novel lung cancer treatment options. University of Colorado Cancer Center

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:22The current state of lung cancer treatment

Brain change link to anti-social behaviour in girlsBrain scans showed significant differences

, 26 August 2020/in E-News /by 3wmedia

The brains of teenage girls with behavioural disorders are different to those of their peers, UK researchers have found. The study of 40 girls revealed differences in the structure of areas linked to empathy and emotions. Previous work has found similar results in boys.
Experts suggest it may be possible to use scans to spot problems early, then offer social or psychological help. An estimated five in every 100 teenagers in the UK are classed as having a conduct disorder.
It is a psychiatric condition which leads people to behave in aggressive and anti-social ways, and which can increase the risk of mental and physical health problems in adulthood. Rates have risen significantly among adolescent girls in recent years, while levels in males have remained about the same.
In this study, funded by the Wellcome Trust and Medical Research Council, UK and Italian researchers conducted brain scans of 22 teenage girls who had conduct disorder and compared them with scans of 20 who did not.
They also checked the scans against others previously taken of teenage boys with conduct disorder. The team found part of the brain called the amygdala was smaller in the brains of male and female teenagers with conduct disorder than in their peers.
The amygdala is involved in picking up whether or not others feel afraid – and plays a role in people feeling fear themselves. Girls with conduct disorder also had less grey matter in an area of the brain called the insula – linked to emotion and understanding your own emotions.
However the same area was larger in boys with conduct disorder than healthy peers, and researchers are not yet sure why that is the case. The brains of those with the worst behaviour were most different from the norm.
Dr Andy Calder, from the MRC cognition and brain sciences unit, who worked on the study, said: ‘The origins of these changes could be due to being born with a particular brain dysfunction or it could be due to exposure to adverse environments such as a distressing experience early in life that could have an impact on the way the brain develops.’
Dr Graeme Fairchild, of the University of Cambridge who also worked on the study, said there were potential uses for the finding.
‘In the US, people are already using brain scans to argue diminished responsibility. I think we’re too early in our understanding to really do that, but it is happening.
‘It would also be possible to use scans where a person is at high risk of offending in the future.
‘More help could be given to the family and, in the same way that someone with language impairment receives extra help, help could be given to teach a person to understand emotions – and the emotions of others – better.’ BBC

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:29Brain change link to anti-social behaviour in girlsBrain scans showed significant differences

Early menopause in mice: A model of human POI

, 26 August 2020/in E-News /by 3wmedia

Scientists have established a genetic mouse model for primary ovarian insufficiency (POI), a human condition in which women experience irregular menstrual cycles and reduced fertility, and early exposure to oestrogen deficiency.
POI affects approximately one in a hundred women. In most cases of primary ovarian insufficiency, the cause is mysterious, although genetics is known to play a causative role. There are no treatments designed to help preserve fertility. Some women with POI retain some ovarian function and a fraction (5-10 percent) have children after receiving the diagnosis.
Having a mouse model could accelerate research on the causes and mechanisms of POI, and could eventually lead to treatments, says Peng Jin, PhD, associate professor of human genetics at Emory University School of Medicine.
The paper was the result of a collaboration between researchers at Emory and the Institute of Zoology, Chinese Academy of Sciences in Beijing. Dahua Chen, PhD, associate director of the State Key Laboratory of Reproductive Biology, is the senior author and postdoctoral fellow Cuiling Lu is the first author. Stephanie Sherman, PhD, professor of human genetics at Emory, is a co-author.
The mouse model builds on research on women who are carriers of a ‘premutation’ for fragile X syndrome, a leading cause of inherited intellectual disability.
The mice have a fragment of a human X chromosome from a fragile X premutation carrier. Other non-genetic mouse models used to study menopause include surgical removal of the ovaries, or exposure of mice to a chemical, 4-vinylcyclohexene diepoxide, which depletes the ovaries.
‘While the fragile X premutation is a leading cause of POI, I think this model will be useful and relevant for all women with this condition,’ Jin says.
Women with the fragile X premutation account for around two percent of spontaneous POI cases and 14 percent of familial POI cases. About 20 percent of women who carry the fragile X premutation experience POI, the disorder now called fragile X-associated POI, or FXPOI.
Fragile X syndrome is caused by the expansion of a ‘triplet repeat’ in a gene (FMR1) that is important for signalling in the brain. In fragile X syndrome, the triplet repeat — three DNA letters (CGG) repeated many times — forces the gene to shut off.
For a woman who carries the premutation, the triplet repeat is not large enough to shut the gene off. There is a risk that it will expand in her children enough to generate fragile X syndrome. In addition, the triplet repeat appears to have an effect on the woman’s ovaries, independently from its influence on the FMR1 gene.
Jin says studying mice that have an analogous genetic alteration will help scientists understand what’s happening to the ovaries in POI. It appears that the RNA coming from the premutation impairs development of the ovarian follicles, the structures in which eggs/oocytes mature.
The research team found that a quarter of premutation-carrying female mice are infertile. When they are housed with male mice, those that do have pups have them a month later on average (12.5 weeks of age compared to 8.5 weeks), and they have fewer pups.
Puberty occurs at roughly five weeks of age in mice, and the premutation mice have alterations in their ovaries already before puberty. At 25 days of age, there are a reduced number of mature follicles in ovaries of the female mice carrying the premutation. Those mice also have altered levels of hormones resembling those of women with POI, such as elevated FSH (follicle stimulating hormone).
The research team found that in the ovaries of mice with the fragile X premutation, ovulation-related genes are less active. In addition, two cellular signalling pathways (Akt/mTOR) are less active in the ovaries, suggesting that drugs that affect those pathways could be used to treat POI. Emory University

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:36Early menopause in mice: A model of human POI

Changes in nerve cells may contribute to the development of mental illness

, 26 August 2020/in E-News /by 3wmedia

Reduced production of myelin, a type of protective nerve fibre that is lost in diseases like multiple sclerosis, may also play a role in the development of mental illness, according to researchers at the Graduate School of Biomedical Sciences at Mount Sinai School of Medicine.
Myelin is an insulating material that wraps around the axon, the threadlike part of a nerve cell through which the cell sends impulses to other nerve cells. New myelin is produced by nerve cells called oligodendrocytes both during development and in adulthood to repair damage in the brain of people with diseases such as multiple sclerosis (MS).
A new study led by Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomics; and Neurology at Mount Sinai, determined that depriving mice of social contact reduced myelin production, demonstrating that the formation of new oligodendrocytes is affected by environmental changes. This research provides further support to earlier evidence of abnormal myelin in a wide range of psychiatric disorders, including autism, anxiety, schizophrenia and depression.
‘We knew that a lack of social interaction early in life impacted myelination in young animals but were unsure if these changes would persist in adulthood,’ said Dr. Casaccia, who is also Chief of the Center of Excellence for Myelin Repair at the Friedman Brain Institute at Mount Sinai School of Medicine. ‘Social isolation of adult mice causes behavioural and structural changes in neurons, but this is the first study to show that it causes myelin dysfunction as well.’
Dr. Casaccia’s team isolated adult mice to determine whether new myelin formation was compromised. After eight weeks, they found that the isolated mice showed signs of social withdrawal. Subsequent brain tissue analyses indicated that the socially isolated mice had lower-than-normal levels of myelin-forming oligodendrocytes in the prefrontal cortex, but not in other areas of the brain. The prefrontal cortex controls complex emotional and cognitive behaviour.
The researchers also found changes in chromatin, the packing material for DNA. As a result, the DNA from the new oligodendrocytes was unavailable for gene expression.
After observing the reduction in myelin production in socially-isolated mice, Dr. Casaccia’s team then re-introduced these mice into a social group. After four weeks, the social withdrawal symptoms and the gene expression changes were reversed.
‘Our study demonstrates that oligodendrocytes generate new myelin as a way to respond to environmental stimuli, and that myelin production is significantly reduced in social isolation,’ said Dr. Casaccia. ‘Abnormalities occur in people with psychiatric conditions characterised by social withdrawal. Other disorders characterised by myelin loss, such as MS, often are associated with depression. Our research emphasises the importance of maintaining a socially stimulating environment in these instances.’
At Mount Sinai, Dr. Casaccia’s laboratory is studying oligodendrocyte formation to identify therapeutic targets for myelin repair. They are screening newly-developed pharmacological compounds in brain cells from rodents and humans for their ability to form new myelin. EurekAlert

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:24Changes in nerve cells may contribute to the development of mental illness

Sticky paper offers cheap, easy solution for paper-based diagnostics

, 26 August 2020/in E-News /by 3wmedia

A current focus in global health research is to make medical tests that are not just cheap, but virtually free. One such strategy is to start with paper – one of humanity’s oldest technologies – and build a device like a home-based pregnancy test that might work for malaria, diabetes or other diseases.
A University of Washington bioengineer recently developed a way to make regular paper stick to medically interesting molecules. The work produced a chemical trick to make paper-based diagnostics using plain paper, the kind found at office supply stores around the world.
‘We wanted to go for the simplest, cheapest starting material, and give it more capability,’ said Daniel Ratner, a UW assistant professor of bioengineering and lead author of the paper
‘We also wanted to make the system as independent of the end applications as possible, something any researcher could plug into.’
Many paper-based diagnostics are made from nitrocellulose, a sticky membrane used in pregnancy tests and by medical researchers to detect proteins, DNA or antibodies in the human immune system.
Ratner hopes to replace that specialised membrane with cheap, ubiquitous paper, and to use it for any type of medical test – not just the big, biological molecules.
The UW technique uses minimal equipment or know-how. The researchers used a cheap, industrial solvent called divinyl sulfone that can be bought by the gallon and has been used for decades as an adhesive. Ratner’s group discovered they could dilute the chemical in water, carefully control the acidity, then pour it into a Ziploc bag and add a stack of paper, shake for a couple of hours, and finally rinse the paper and let it dry.
The dried paper feels smooth to the touch but is sticky to all kinds of chemicals that could be of medical interest: proteins, antibodies and DNA, for example, as well as sugars and the small-molecule drugs used to treat most medical conditions.
‘We want to develop something to not just ask a single question but ask many personal health questions,’ Ratner said. ‘‘Is there protein in the urine? Is this person diabetic? Do they have malaria or influenza?’’
To test their idea, the researchers ran the treated paper through an inkjet printer where the cartridge ink had been replaced with biomolecules, in this case a small sugar called galactose that attaches to human cells. They printed the biomolecules onto the sticky paper in an invisible pattern. Exposing that paper to fluorescent ricin, a poison that sticks to galactose, showed that the poison was present.
Now that they have proven their concept, Ratner said, they hope other groups will use the paper to develop actual diagnostic tests. University of Washington

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:31Sticky paper offers cheap, easy solution for paper-based diagnostics

Researchers uncover gender differences in the effects of long-term alcoholism

, 26 August 2020/in E-News /by 3wmedia

Researchers from Boston University School of Medicine (BUSM) and Veterans Affairs (VA) Boston Healthcare System have demonstrated that the effects on white matter brain volume from long-term alcohol abuse are different for men and women. The study also suggests that with abstinence, women recover their white matter brain volume more quickly than men.
The study was led by Susan Mosher Ruiz, PhD, postdoctoral research scientist in the Laboratory for Neuropsychology at BUSM and research scientist at the VA Boston Healthcare System, and Marlene Oscar Berman, PhD, professor of psychiatry, neurology and anatomy and neurobiology at BUSM and research career scientist at the VA Boston Healthcare System.
In previous research, alcoholism has been associated with white matter pathology. White matter forms the connections between neurons, allowing communication between different areas of the brain. While previous neuroimaging studies have shown an association between alcoholism and white matter reduction, this study furthered the understanding of this effect by examining gender differences and utilising a novel region-of-interest approach.
The research team employed structural magnetic resonance imaging (MRI) to determine the effects of drinking history and gender on white matter volume. They examined brain images from 42 abstinent alcoholic men and women who drank heavily for more than five years and 42 non-alcoholic control men and women. Looking at the correlation between years of alcohol abuse and white matter volume, the researchers found that a greater number of years of alcohol abuse was associated with smaller white matter volumes in the abstinent alcoholic men and women. In the men, the decrease was observed in the corpus callosum while in women, this effect was observed in cortical white matter regions.
‘We believe that many of the cognitive and emotional deficits observed in people with chronic alcoholism, including memory problems and flat affect, are related to disconnections that result from a loss of white matter,’ said Mosher Ruiz.
The researchers also examined if the average number of drinks consumed per day was associated with reduced white matter volume. They found that the number of daily drinks did have a strong impact on alcoholic women, and the volume loss was one and a half to two percent for each additional daily drink. Additionally, there was an eight to 10 percent increase in the size of the brain ventricles, which are areas filled with cerebrospinal fluid (CSF) that play a protective role in the brain. When white matter dies, CSF produced in the ventricles fills the ventricular space.
Recovery of white matter brain volume also was examined. They found that, in men, the corpus callosum recovered at a rate of one percent per year for each additional year of abstinence. For people who abstained less than a year, the researchers found evidence of increased white matter volume and decreased ventricular volume in women, but not at all in men. However, for people in recovery for more than a year, those signs of recovery disappeared in women and became apparent in men.
‘These findings preliminarily suggest that restoration and recovery of the brain’s white matter among alcoholics occurs later in abstinence for men than for women,’ said Mosher Ruiz. ‘We hope that additional research in this area can help lead to improved treatment methods that include educating both alcoholic men and women about the harmful effects of excessive drinking and the potential for recovery with sustained abstinence.’ Boston University Medical Center

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:41Researchers uncover gender differences in the effects of long-term alcoholism

Detrimental effect of obesity on lesions associated with Alzheimer’s disease

, 26 August 2020/in E-News /by 3wmedia

Researchers from Inserm and the Université Lille/Université Lille Nord de France have recently used a neurodegeneration model of Alzheimer’s disease to provide experimental evidence of the relationship between obesity and disorders linked to the tau protein. This research was conducted on mice and it corroborates the theory that metabolic anomalies contribute massively to the development of dementia.
In France, more than 860,000 people suffer from Alzheimer’s disease and related disorders, making them the largest cause of age-related loss of intellectual function. Cognitive impairments observed in Alzheimer’s disease result from the accumulation of abnormal tau proteins in nerve cells undergoing degeneration. We know that obesity, a major risk factor in the development of insulin resistance and type 2 diabetes, increases the risk of dementia during the ageing process. However, the effects of obesity on ‘Taupathies’ (i.e. tau protein-related disorders), including Alzheimer’s disease, were not clearly understood. In particular, researchers assumed that insulin resistance played a major role in terms of the effects of obesity.
The ‘Alzheimer & Tauopathies’ team from mixed research unit 837 (Inserm/Université Lille 2/Université Lille Nord de France) directed by Dr. Luc Buée, in collaboration with mixed research unit 1011 ‘Nuclear receptors, cardiovascular diseases and diabetes’, have just demonstrated, in mice, that obese subjects develop aggravated disorders. To achieve this result, young transgenic mice, who develop tau-related neurodegeneration progressively with age, were put on a high-fat diet for five months, leading to progressive obesity.
 
‘At the end of this diet, the obese mice had developed an aggravated disorder both from the point of view of memory and modifications to the Tau protein’ explains David Blum, in charge of research at Inserm.
This study uses a neurodenegeneration model of Alzheimer’s disease to provide experimental evidence of the relationship between obesity and disorders linked to the tau protein. Furthermore, it indicates that insulin resistance is not the aggravating factor, as was suggested in previous studies.
‘Our research supports the theory that environmental factors contribute massively to the development of this neurodegenerative disorder’ underlines the researcher. ‘Our work is now focussing on identifying the factors responsible for this aggravation’ he adds. Inserm

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:19Detrimental effect of obesity on lesions associated with Alzheimer’s disease
Page 89 of 227«‹8788899091›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
13 November 2025

New Chromsystems Product for Antiepileptic Drugs Testing

11 November 2025

Trusted analytical solutions for reliable results

10 November 2025

Chromsystems | Therapeutic Drug Monitoring by LC-MS/MS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription